Judah Frommer
Stock Analyst at Morgan Stanley
(4.09)
# 505
Out of 5,150 analysts
183
Total ratings
61.15%
Success rate
8.92%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Maintains: Overweight | $191 → $201 | $177.79 | +13.05% | 2 | Mar 3, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiates: Overweight | $28 | $14.68 | +90.74% | 1 | Mar 3, 2026 | |
| GMAB Genmab | Reinstates: Equal-Weight | $34 | $28.18 | +20.65% | 1 | Feb 16, 2026 | |
| RGNX REGENXBIO | Maintains: Overweight | $25 → $18 | $9.14 | +96.94% | 3 | Feb 10, 2026 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $101 → $145 | $116.77 | +24.18% | 4 | Jan 9, 2026 | |
| ZBIO Zenas BioPharma | Downgrades: Equal-Weight | $37 → $19 | $25.82 | -26.41% | 2 | Jan 6, 2026 | |
| EVMN Evommune | Initiates: Overweight | $36 | $23.59 | +52.61% | 1 | Dec 1, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Overweight | $18 → $19 | $12.92 | +47.06% | 2 | Nov 14, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $19.86 | +30.92% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $29.54 | +45.57% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $31 → $22 | $33.69 | -34.70% | 3 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $6 | $8.93 | -32.81% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $81 → $106 | $114.30 | -7.26% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $18.54 | +88.78% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $2.46 | +21.95% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $1.42 | +2,716.90% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $3.31 | +292.75% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $34.42 | -33.18% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $64.29 | -22.23% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $16.09 | +776.32% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $3.69 | +143.90% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $31.18 | -29.44% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $4.95 | +41.41% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $8.35 | -4.19% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $74.63 | -38.36% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $2.91 | +140.55% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $9.04 | +508.41% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $149.88 | -69.31% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $90.82 | -46.05% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $1,006.74 | -63.25% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $93.14 | -66.72% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $87.63 | -13.27% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $151.60 | +20.05% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $117.85 | -9.21% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $108.79 | -12.68% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $17.10 | +5.26% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $220.52 | -47.40% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $99.98 | -61.99% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $76.45 | -71.22% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $67.99 | -48.52% | 9 | Apr 29, 2020 |
Belite Bio
Mar 3, 2026
Maintains: Overweight
Price Target: $191 → $201
Current: $177.79
Upside: +13.05%
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Overweight
Price Target: $28
Current: $14.68
Upside: +90.74%
Genmab
Feb 16, 2026
Reinstates: Equal-Weight
Price Target: $34
Current: $28.18
Upside: +20.65%
REGENXBIO
Feb 10, 2026
Maintains: Overweight
Price Target: $25 → $18
Current: $9.14
Upside: +96.94%
ABIVAX Société Anonyme
Jan 9, 2026
Maintains: Overweight
Price Target: $101 → $145
Current: $116.77
Upside: +24.18%
Zenas BioPharma
Jan 6, 2026
Downgrades: Equal-Weight
Price Target: $37 → $19
Current: $25.82
Upside: -26.41%
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: $36
Current: $23.59
Upside: +52.61%
Trevi Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $12.92
Upside: +47.06%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $19.86
Upside: +30.92%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $29.54
Upside: +45.57%
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $33.69
Upside: -34.70%
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $8.93
Upside: -32.81%
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $114.30
Upside: -7.26%
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $18.54
Upside: +88.78%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.46
Upside: +21.95%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $1.42
Upside: +2,716.90%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $3.31
Upside: +292.75%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $34.42
Upside: -33.18%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $64.29
Upside: -22.23%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $16.09
Upside: +776.32%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $3.69
Upside: +143.90%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $31.18
Upside: -29.44%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $4.95
Upside: +41.41%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $8.35
Upside: -4.19%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $74.63
Upside: -38.36%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $2.91
Upside: +140.55%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $9.04
Upside: +508.41%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $149.88
Upside: -69.31%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $90.82
Upside: -46.05%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $1,006.74
Upside: -63.25%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $93.14
Upside: -66.72%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $87.63
Upside: -13.27%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $151.60
Upside: +20.05%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $117.85
Upside: -9.21%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $108.79
Upside: -12.68%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $17.10
Upside: +5.26%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $220.52
Upside: -47.40%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $99.98
Upside: -61.99%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $76.45
Upside: -71.22%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $67.99
Upside: -48.52%